Over the past twelve months, cardiology has produced an unusually dense run of lipid-related publications. A new US dyslipidemia guideline replaced the 2018 cholesterol guideline, a large outcomes trial of a PCSK9 antibody in patients with no prior heart attack or stroke was published, and the European Society of Cardiology Congress 2026 added further data on early LDL-cholesterol lowering. This article summarises what those sources report, so that hospital pharmacists, cardiology departments and procurement teams can follow the discussion. A.K. Pharma, a medicine distributor in Delhi and pharmaceutical distributor in Delhi, supplies PCSK9-pathway medicines to healthcare institutions across India. We are not clinicians; we do not advise on who should receive any therapy.
Topics
